scholarly journals Predictors of survival rate in patients with pancreatic cancer: A multi‐center analytical study in Iran

2021 ◽  
Author(s):  
Mansour Bahardoust ◽  
Mohammad Ali Abyazi ◽  
Sayed Ali Emami ◽  
Parmida Ghadimi ◽  
Mehrdad Khodabandeh ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Analytical Study

scholarly journals New Aspects of the Epigenetics of Pancreatic Carcinogenesis

Epigenomes ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 18
Author(s):  
Murat Toruner ◽  
Martin E. Fernandez-Zapico ◽  
Christopher L. Pin
Keyword(s):  
Pancreatic Cancer ◽  
Dna Methylation ◽  
Survival Rate ◽  
Epigenetic Mechanisms ◽  
Therapeutic Approaches ◽  
Cancer Epigenetics ◽  
Pancreatic Carcinogenesis ◽  
New Therapeutic Approaches ◽  
Environmental Events ◽  
Underlying Pathogenesis

Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic nor environmental factors completely explain susceptibility or pathogenesis. Defining the links between genetic and environmental events represents an opportunity to understand the pathogenesis of pancreatic cancer. Epigenetics, the study of mitotically heritable changes in genome function without a change in nucleotide sequence, is an emerging field of research in pancreatic cancer. The main epigenetic mechanisms include DNA methylation, histone modifications and RNA interference, all of which are altered by changes to the environment. Epigenetic mechanisms are being investigated to clarify the underlying pathogenesis of pancreatic cancer including an increasing number of studies examining the role as possible diagnostic and prognostic biomarkers. These mechanisms also provide targets for promising new therapeutic approaches for this devastating malignancy.

scholarly journals Advance in Pancreatic Cancer Diagnosis and Therapy

2020 ◽  
Author(s):  
Xiaojie Cai ◽  
Jie Gao ◽  
Yanfang Liu ◽  
Ming Wang ◽  
Qiulian Ma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cells ◽  
Survival Rate ◽  
Tumor Microenvironment ◽  
Cancer Diagnosis ◽  
Treatment Resistance ◽  
Serum Markers ◽  
Molecular Probes ◽  
Cancer Death ◽  
Cancer Diagnosis And Therapy

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

scholarly journals Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene via Maintaining Mitochondrial Function in Pancreatic Cancer

2021 ◽  
Author(s):  
Qiongying Hu ◽  
Li Wang ◽  
Yi Zhang ◽  
Bole Tian ◽  
ziyi Zhao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Pancreatic Cancer Cell ◽  
Mitochondrial Gene ◽  
Cancer Cell Lines ◽  
Tumor Formation ◽  
Negatively Associated

Abstract BackgroundThe mitochondrial-associated protein LRPPRC exerts multiple functions involved in physiological processes, including mitochondrial gene translation, cell cycle progression and tumorigenesis. Previously, LRPPRC was reported to regulate mitophagy by interacting with Bcl-2 and Beclin 1 and thus modifying the activation of PI3KCIII and autophagy. Considering that LRPPRC was found to be negatively associated with survival rate, we hypothesize that LRPPRC may be involved in pancreatic cancer progression via its regulation of autophagy. Methodsreal-time quantitative PCR was performed to detect the expression of LRPPRC in 90 paired pancreatic cancer and adjacent tissues and five pancreatic cancer cell lines. Mitochondrial reactive oxidative species (ROS) level and function were measured. Mitophagy was measured by performing to detect LC3 level. ResultsBy performing RT-qPCR, the association of LRPPRC with the prognosis of pancreatic cancer was established and pancreatic cancer tissues had significantly higher LRPPRC expression than adjacent tissues. LRPPRC was negatively associated with the overall survival rate. LRPPRC was also upregulated in pancreatic cancer cell lines. Knockdown of LRPPRC promoted ROS accumulation, decreased mitochondrial membrane potential (MMP), promoted autophagy/mitophagy, and induced mitochondrial dysfunction. Subsequently, knockdown of LRPPRC inhibited malignant behaviors in PANC-1 cells, including proliferation, migration, invasion, tumor formation and chemoresistance to gemcitabine. Finally, by inhibiting autophagy/mitophagy using 3-MA, the inhibitory effect of LRPPRC knockdown on proliferation was reversed. ConclusionTaken together, our results indicate that LRPPRC may act as an oncogene via maintaining mitochondrial homoeostasis and could be used as a predictive marker for patient prognosis in pancreatic cancer.

Correlation of Nitrite Oxide with Severity and Survival Rate of Sepsis Patients

2021 ◽  
Vol 28 (1) ◽  
pp. 61
Author(s):  
Sotianingsih Sotianingsih ◽  
Budi Mulyono ◽  
Andaru Dahesihdewi ◽  
Samsirun Halim ◽  
Ahmad Syauqi
Keyword(s):  
Nitric Oxide ◽  
Statistical Analysis ◽  
Survival Rate ◽  
Analytical Study ◽  
P Values ◽  
Nitrite Oxide ◽  
Risk Of Death ◽  
Survivor Group ◽  
Kinetics Of ◽  
Difference Test

The objective of this research was to determine the correlation between Nitric Oxide (NO) levels with the severity ofsepsis, to describe the kinetics of NO levels, and to evaluate it in predicting mortality. This research was a longitudinal cohortobservational analytical study. The variables were serum NO levels and SOFA scores, which were serially evaluated. Thecorrelation test and difference test were used for statistical analysis. The survivor and the non-survivor group consisted of 14(41.18%) and 20 (58.82%) patients, respectively. There was a correlation between serum NO levels and the SOFA score at the24-hour observation (r=0.403; p=0.041). Non-parametric Mann-Whitney test showed that there was no kinetics of NOth levels at 0, 24, 72, and 144-hour observation (p-values =0.897 and 0.703, respectively). NO levels > 111,16 μmol/L at the 24hour could predict the risk of death with hazard ratio 4.7 compared to NO levels < 111,16 μmol/L. The survival rate ofpatients with serum NO levels <111,16 μmol/L and > 111,16 μmol/L was 83.3% and 37.5%, respectively. There was acorrelation between serum NO levels and SOFA scores at the 24-hour observation. However, there was no kinetics of NOlevels at serial evaluations. Nitric oxide levels with a cut-off of 111,16 μmol/L at 24 hours could predict the survival of septicth patients. Utilization of serum NO level at 24 hour can be used to evaluate the severity of septic patients and aggressivemanagement if there is an increase in serum NO levels > 111,16 μmol/L at 24 hours.

Cancer Survival Is (Mostly) Improving

Pained ◽  
2020 ◽  
pp. 245-246
Author(s):  
Michael D. Stein ◽  
Sandro Galea
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Diagnosis ◽  
Cancer Survival ◽  
Prostate Cancer Screening ◽  
Survival Rates ◽  
The United States ◽  
Cervical Cancers

This chapter discusses how the 5-year survival rates for the most common cancers in the United States improved by nearly 20% since the 1970s. While promising overall, low survival rates persist for pancreatic, liver, lung, esophageal, brain, and many other cancers. Meanwhile, 5-year survival for uterine and cervical cancers worsened. Pancreatic cancer has the lowest 5-year survival rate at 8.2%. In contrast, prostate cancer had the greatest 5-year survival increase from 67.8% to 98.6%, most likely reflecting a substantial uptick in prostate cancer screening and early detection. Five-year survival with leukemia also improved significantly, from 34.2% to 60.6%, likely resulting from improved treatments. As such, in both detection and treatment, the United States is making progress. For the millions of Americans who face a cancer diagnosis, this is cause for hope.

scholarly journals Omics Approaches in Pancreatic Adenocarcinoma

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1052
Author(s):  
Iranzu González-Boja ◽  
Antonio Viúdez ◽  
Saioa Goñi ◽  
Enrique Santamaria ◽  
Estefania Carrasco-García ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Curative Intent ◽  
Pancreatic Cancers ◽  
Wide Range ◽  
Prevention And Treatment ◽  
Shed Light

Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.

scholarly journals Chinese Herbal Medicine Effectively Prolongs the Overall Survival of Pancreatic Cancer Patients: A Case Series

2019 ◽  
Vol 18 ◽  
pp. 153473541982883 ◽  
Author(s):  
Wendy Wong ◽  
Bing Zhong Chen ◽  
Allyson Kin Yan Lee ◽  
Adrian Ho Cheung Chan ◽  
Justin Che Yuen Wu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Herbal Medicine ◽  
Cancer Patients ◽  
Chinese Herbal Medicine ◽  
Western Medicine ◽  
Combined Treatment ◽  
Case Series ◽  
Chinese Herbal

Background and Aims: Pancreatic cancer has the lowest survival rate of all cancers (4%), and it accounts for 1.9% of new cancer cases in Hong Kong. Combined treatment with Chinese herbal medicine (CHM) and Western medicine has yielded promising results, leading to improved prognosis and overall survival. This retrospective case series aimed to illustrate the improved survival and quality of life outcomes of pancreatic cancer patients administered CHM based on traditional Chinese medicine theory. Methods: To investigate the effectiveness of CHM in prolonging overall survival, 182 patients diagnosed with pancreatic cancer who received CHM treatment were observed from 2005 to 2015. Results: One hundred eighty-two pancreatic cancer patients were treated with CHM; 21 patients died. The mean and median survival of these patients were 29.6 and 15.2 months, respectively; the 1-year survival rate was 76% (range = 4 months to 9 years). These results are better than those reported in patients treated with Western medicine, suggesting the need for further study of CHM. Conclusion: A superior clinical outcome may be obtained with CHM treatment. The case series illustrates the potential benefits and safety issues of CHM in pancreatic cancer patients that could be relevant for developing strategies to increase individualization of pancreatic cancer treatment and improve survival. This study may facilitate interprofessional communication and improved clinical management of pancreatic cancer patients.

Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy

Nanoscale ◽  
2019 ◽  
Vol 11 (35) ◽  
pp. 16476-16487 ◽  
Author(s):  
Ying Hu ◽  
Xue Chen ◽  
Yingying Xu ◽  
Xianru Han ◽  
Mou Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Effective Treatment ◽  
Patient Survival ◽  
Treatment Options ◽  
Hierarchical Assembly ◽  
Albumin Nanoparticles ◽  
Poor Patient ◽  
Patient Survival Rate ◽  
Poor Patient Survival

Pancreatic cancer is a highly malignant carcinoma with limited effective treatment options, resulting in a poor patient survival rate of less than 5%.

scholarly journals Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers

2017 ◽  
Vol 9 ◽  
pp. 1179299X1769014 ◽  
Author(s):  
Jingzhu Nan ◽  
Juan Li ◽  
Xiujuan Li ◽  
Guanghong Guo ◽  
Xinyu Wen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Carcinoembryonic Antigen ◽  
Youden Index ◽  
Rank Test ◽  
Prognostic Information ◽  
Treatment Implementation ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index. The data were analyzed by the Kaplan-Meier curves generated by the log-rank test and Cox multivariate analysis. Results: The overall survival rate for all the patients was 71.11%. The 3-year survival rate of patients with prostate, breast, gastric, and pancreatic cancers was 81.69%, 95.65%, 54.55%, and 51.61%, respectively. The 3-year survival rate showed significant statistical differences between patients with serum CEA levels <2.885 µg/L and those with serum CEA levels ⩾2.885 µg/L ( P < .001). The statistical differences of the 3-year survival rate also existed in the men ( P = .010) or women group ( P < .001), as well as in the 3 different types of cancer, which include breast cancer ( P = .025), gastric cancer ( P = .001), and pancreatic cancer ( P = .047). Conclusions: Serum CEA levels can provide additional prognostic information and may be useful in treatment implementation for patients with breast, gastric, or pancreatic cancer.

scholarly journals The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e76052 ◽  
Author(s):  
Jianfeng Luo ◽  
Linhai Xiao ◽  
Chunxiao Wu ◽  
Ying Zheng ◽  
Naiqing Zhao
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Population Based
Sign in / Sign up

Export Citation Format

Share Document